Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Kaposi's Sarcoma Clinical Trials

A listing of Kaposi's Sarcoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (15) clinical trials

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

Infection with Kaposi sarcoma herpesvirus (KSHV, or human herpesvirus-8) causes Kaposi sarcoma (KS). These virally associated diseases occur more frequently in HIV-infected individuals, but can also be found in HIV-uninfected population. Evolution of immunosuppressive mechanisms presumably plays a permissive role in the development, progression and recurrence of these virus-associated cancers ...

Phase N/A

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

PRIMARY OBJECTIVES: I. To determine the efficacy of a therapeutic escalation strategy consisting of standard dose nelfinavir (nelfinavir mesylate), followed by high dose nelfinavir, for the treatment of Kaposi sarcoma (KS) tumor lesions. With 36 evaluable participants, the null hypothesis will be rejected if 11 or more participants respond. SECONDARY ...

Phase

Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya

Compression therapy is a well-established cornerstone therapy and part of routine clinical care for chronic leg ulcers from venous disease and lymphedema, including Kaposi sarcoma (KS)-associated lymphedema. Chronic leg ulcers, from trauma or chronic venous disease, and lymphedema have a significant impact on quality of life, driven by pain, foul ...

Phase N/A

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

PRIMARY OBJECTIVES: I. To evaluate the clinical response and toxicity of recombinant EphB4-HSA fusion protein (sEphB4-HSA) (at initial dosing of 15 mg/kg every 2 weeks) in participants with Kaposi sarcoma. SECONDARY OBJECTIVES: I. To assess the safety of sEphB4-HSA in participants with Kaposi sarcoma (KS). II. To determine trough level ...

Phase

Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma

The investigators will perform a cross-sectional study of 500 patients in routine clinical care settings who are suspected to have KS on clinical grounds and for whom skin punch biopsy and histopathological examination is indicated as part of standard of care. Patients will be evaluated with both the gold standard ...

Phase N/A

Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma

Kaposi sarcoma (KS) is an angioproliferative disease associated with infection by the Human Immune Deficiency virus (HIV), mediated by cytokines, in which the presence of Human Herpes-Virus 8 (HHV-8) and immunosuppression are essential for the disease process. It has an unpredictable course and can be indolent or can entertain a ...

Phase

Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma

Classic and endemic Kaposi's sarcoma (KS) are lymph angio proliferations associated with human herpes virus 8 (HHV8) which treatment is poorly codified. Chemotherapies give at best 30-60% of transient responses. While interferon responses are frequent, this drug is often poorly tolerated in elderly patients. Therefore new therapies are needed. Classic ...

Phase

124I-FIAU Imaging in EBV and KSHV Associated Cancers

EBV and KSHV are associated with a variety of malignancies including some lymphomas, carcinomas and other malignancies. We anticipate that viral TK expression will differ among tumor types and will be adjusted with standard chemotherapies and some investigational agents. This exploratory study is aimed in part at evaluating whether standard ...

Phase N/A

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) Injection in Kaposi Sarcoma (KS)

This is a prospective, single-center, open-label, within-subject study of intravenously injected Tc 99m tilmanocept in the localization and detection of cutaneous and non-cutaneous KS tumor(s) in subjects with biopsy-confirmed KS. Six IV doses (g/mCi) of tilmanocept will be evaluated in cohort groups. This study is designed to evaluate the safety ...

Phase N/A

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Sphingosine Kinase (SK) is an innovative target for anti-cancer therapy due to its critical role in lipid metabolism which drives cancer cell growth. We have found that the SK inhibitor ABC294640 (which is formulated for clinical use as an oral agent) significantly inhibits and reverses progression of virus-associated DLBCL in ...

Phase